The Chhattisgarh government’s health department is taking strict action to ensure the quality of medicines supplied to healthcare facilities. A show cause notice has been served to M/s. Effi Parenterals, signaling the potential for the company to be blacklisted due to issues with the quality of their drugs.
The department rigorously tests all drug batches before they are distributed to health institutions. This involves random sampling and testing in NABL-accredited labs to verify that the medications meet the required standards. Only those that pass the tests are approved for distribution.
Recently, several batches of Albendazole Tablets IP 400 mg (Drug Code – D12) supplied by M/s. Effi Parenterals were tested at the State Drug Testing and Research Laboratory, Raipur. Batches PGT25451, PGT25450, PGT25480, and PGT25229 failed the quality tests. As a result, the health department, upholding its zero-tolerance stance on quality, has initiated proceedings to blacklist the company. The firm has been directed to retrieve the substandard drug batches from all warehouses.
It is important to note that M/s. Effi Parenterals had previously supplied 14 batches of the same medication, Albendazole Tablets IP 400 mg. These earlier batches had successfully passed the NABL tests and were subsequently distributed to the healthcare facilities.